Posted: March 25, 2022 at 2:21 am
– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH –
Original post:
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Posted: March 25, 2022 at 2:21 am
On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22
See the original post here:
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
Posted: March 25, 2022 at 2:21 am
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and full year ended December 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.
Originally posted here:
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
Posted: March 25, 2022 at 2:21 am
BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.
Read more from the original source:
SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
Posted: March 25, 2022 at 2:21 am
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.
More:
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
Posted: March 25, 2022 at 2:21 am
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -
Read the original post:
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
Posted: March 25, 2022 at 2:21 am
WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2021 financial results.
Read more here:
Kane Biotech Announces Fourth Quarter and Full Year 2021 Financial Results
Posted: March 25, 2022 at 2:21 am
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- ?Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021.
See the rest here:
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
Posted: March 25, 2022 at 2:21 am
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, announced today that it will report earnings results for its fourth quarter and full year ended December 31, 2021, on Thursday March 31, 2022, before the financial markets open.
See the rest here:
Auxly to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
Posted: March 25, 2022 at 2:21 am
-- Proposal of one-tier board structure & appointment of three new directors --Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.
Original post:
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
